Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiko Okikawa

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
International Journal of Hematology|June 29, 2004
Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cellsYoshiko Okikawa, Akira Sakai, Yasuo Takimoto, et al.
Hematology (Amsterdam, Netherlands)|July 4, 2007
Prognosis value of atrial natriuretic peptide and brain natriuretic peptide for heart failure in patients undergoing allogeneic bone marrow transplantationHiroyuki Takatsuka, Toshiyuki Nakajima, Kaori Nomura, et al.
Clinical Transplantation|September 14, 2006
Changes of clotting factors (7, 9 and 10) and hepatocyte growth factor in patients with thrombotic microangiopathy after bone marrow transplantationHiroyuki Takatsuka, Toshiyuki Nakajima, Kaori Nomura, et al.
International Journal of Hematology|May 26, 2005
The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agentsYoshiaki Kuroda, Akira Sakai, Yoshiko Okikawa, et al.
British Journal of Haematology|September 15, 2007
Connective tissue growth factor is an indicator of bone involvement in multiple myeloma, but matrix metalloproteinase-9 is notShoso Munemasa, Akira Sakai, Yoshiaki Kuroda, et al.
Journal of Blood Medicine|November 22, 2021
Outcomes of Patients Who Undergo Transfusion of Fresh Frozen Plasma: A Prospective, Observational, Multicentre Cohort Study in Hiroshima, JapanAya Sugiyama, Teruhisa Fujii, Yoshiko Okikawa, et al.
BMC Cancer|June 23, 2014
Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survivalTakayoshi Kiba, Takuo Ito, Toshihisa Nakashima, et al.
International Journal of Oncology|November 21, 2008
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myelomaYoshiaki Kuroda, Akira Sakai, Naohiro Tsuyama, et al.
Targeted Oncology|January 21, 2021
Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with NivolumabYoshiyasu Kono, Yasuhiro Choda, Masahiro Nakagawa, et al.
International Journal of Oncology|August 4, 2004
Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cellsYuta Katayama, Akira Sakai, Yoshiko Okikawa, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
International Journal of Hematology|June 29, 2004
Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cellsYoshiko Okikawa, Akira Sakai, Yasuo Takimoto, et al.
Hematology (Amsterdam, Netherlands)|July 4, 2007
Prognosis value of atrial natriuretic peptide and brain natriuretic peptide for heart failure in patients undergoing allogeneic bone marrow transplantationHiroyuki Takatsuka, Toshiyuki Nakajima, Kaori Nomura, et al.
Clinical Transplantation|September 14, 2006
Changes of clotting factors (7, 9 and 10) and hepatocyte growth factor in patients with thrombotic microangiopathy after bone marrow transplantationHiroyuki Takatsuka, Toshiyuki Nakajima, Kaori Nomura, et al.
International Journal of Hematology|May 26, 2005
The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agentsYoshiaki Kuroda, Akira Sakai, Yoshiko Okikawa, et al.
British Journal of Haematology|September 15, 2007
Connective tissue growth factor is an indicator of bone involvement in multiple myeloma, but matrix metalloproteinase-9 is notShoso Munemasa, Akira Sakai, Yoshiaki Kuroda, et al.
Journal of Blood Medicine|November 22, 2021
Outcomes of Patients Who Undergo Transfusion of Fresh Frozen Plasma: A Prospective, Observational, Multicentre Cohort Study in Hiroshima, JapanAya Sugiyama, Teruhisa Fujii, Yoshiko Okikawa, et al.
BMC Cancer|June 23, 2014
Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survivalTakayoshi Kiba, Takuo Ito, Toshihisa Nakashima, et al.
International Journal of Oncology|November 21, 2008
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myelomaYoshiaki Kuroda, Akira Sakai, Naohiro Tsuyama, et al.
Targeted Oncology|January 21, 2021
Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with NivolumabYoshiyasu Kono, Yasuhiro Choda, Masahiro Nakagawa, et al.
International Journal of Oncology|August 4, 2004
Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cellsYuta Katayama, Akira Sakai, Yoshiko Okikawa, et al.
Pageof 3